Production and development of multi-doses, with or without preservatives

To meet our clients’ needs and market demands, we offer a range of aseptic multi-dose filling solutions. Unither offers development and manufacturing services for technologies for preservative-free multi-doses (PFMD) and multi-doses with preservatives.

Stérile
Sterile Single-Dose Units, Preservative-Free
Volume_Filling (1)
Filling Volume: Multidose with Preservatives: 1.5 to 15 ml / MDSC: 5 to 15 ml
Volume_Filling (2)
Classic and flexible vials, several presentations possible
Multidoses
personnalisation
Aptar OSD® and Nemera Novelia® Technologies
solutions supensions
Formulation Types: ophthalmic solutions and suspensions, otology products
statut
Statuses: pharmaceuticals, medical devices, OTC, cosmetics ...

Benefits of multi-doses

Choosing multidose technology ensures continuity of chronic ophthalmic treatments.

  • Improved product tolerance
  • Prevention of microbial contamination for the entire treatment period
  • Complement to the BFS ophthalmic range
  • The vial is easier to transport than multiple single-dose vials and generates no product waste, making the format more environmentally friendly.
  • Calibrated drops
  • Easy to use
  • Suitable for chronic diseases
  • Suitable for a range of therapeutic areas: allergic, anti-infective, anti-inflammatory, glaucoma, dry eye syndrome (DES), ocular hygiene solutions, new chemical entities (NCE), etc.

Manufacturing sites

Regulatory authorizations, standards and certifications: access the full list

Out-licensing - our turnkey documentation and products in Multi-Dose packaging

 Table: Out-licensing - our turnkey documentation and products in Multi-Dose packaging
Multi-dose Volume Category Status Dossier Country
Sodium Carmellose (CMC) 0.5% 10.15 ml Ophthalmic MD October 2026 - ANVISA Brazil
Sodium Hyaluronate 0.15% 10 ml Ophthalmic MD October 2026 - ANVISA Brazil
Sodium Carmellose (CMC) 0.5% + Sodium Hyaluronate 0.10% + Glycerol 0.9% 10 ml Ophthalmic MD Q1 2027 - ANVISA Brazil
EYELEEN - Carragelose eye drops 3.2 mg/ml (Preservative free) 10 ml Ophthalmic MD (IIa) CE Marking Contact us

End-to-end support from the initial phases: from concept to product

Manufacturing

From technology transfer to industrial manufacturing, from small clinical batches to commercial volumes.

Development

Formulation and analytical development, manufacture of clinical batches, stability studies, and expertise in ophthalmic development.

Out-licensing

Access medicines and medical devices that are ready to be registered and marketed.
 Content type:  Resource  Resource

Carragelose® Eyedrops

Discover a New Approach to Dry Eye Relief Dry Eye Disease (DED) affects millions of people worldwide, often leading to…

Do you have any questions? - Consult our FAQ

Unither offers a full ophthalmic technology platform, including PFMD (preservative-free multidose) and standard multidose with preservatives, alongside BFS unit-dose.
This enables a tailored approach, selecting the most relevant format based on treatment duration, patient needs and market positioning, rather than a one-size-fits-all solution.

One of the main risks in ophthalmic projects is the gap between development and industrial production.
Unither enables seamless scale-up with:

GMP manufacturing from 3 L to 2,000 L
pilot workshops and industrial equipment
reproducible processes from early-stage to commercial supply

Maintaining product safety after opening is a key challenge in multidose systems.

Unither addresses this through:

engineered sterility strategies for PFMD
robust microbiological protection for preserved multidose
ensuring safe and reliable use across the full treatment period.

Selecting between preservative-free multidose (PFMD) and multidose with preservatives depends on treatment duration, patient sensitivity and market positioning.
Unither supports this decision early, helping you define the optimal balance between tolerability, sterility requirements and industrial feasibility, based on your product and target population.